<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="nihpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC3076530/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Cerivastatin, Genetic Variants, and the Risk of Rhabdomyolysis</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css"><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076530/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="Pharmacogenetics and genomics"><meta name="citation_title" content="Cerivastatin, Genetic Variants, and the Risk of Rhabdomyolysis"><meta name="citation_authors" content="Kristin D. Marciante, Jon P. Durda, Susan R. Heckbert, Thomas Lumley, Ken Rice, Barbara McKnight, Rheem A. Totah, Bani Tamraz, Deanna L. Kroetz, Hisayo Fukushima, Rüdiger Kaspera, Joshua C. Bis, Nicole L. Glazer, Guo Li, Thomas R. Austin, Kent D. Taylor, Jerome I. Rotter, Cashell E. Jaquish, Pui-Yan Kwok, Russell P. Tracy, Bruce M. Psaty"><meta name="citation_date" content="May 2011"><meta name="citation_issue" content="5"><meta name="citation_volume" content="21"><meta name="citation_firstpage" content="280"><meta name="citation_doi" content="10.1097/FPC.0b013e328343dd7d"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3076530/?report=abstract"><meta name="citation_pmid" content="21386754"><meta name="DC.Title" content="Cerivastatin, Genetic Variants, and the Risk of Rhabdomyolysis"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="NIH Public Access"><meta name="DC.Contributor" content="Kristin D. Marciante"><meta name="DC.Contributor" content="Jon P. Durda"><meta name="DC.Contributor" content="Susan R. Heckbert"><meta name="DC.Contributor" content="Thomas Lumley"><meta name="DC.Contributor" content="Ken Rice"><meta name="DC.Contributor" content="Barbara McKnight"><meta name="DC.Contributor" content="Rheem A. Totah"><meta name="DC.Contributor" content="Bani Tamraz"><meta name="DC.Contributor" content="Deanna L. Kroetz"><meta name="DC.Contributor" content="Hisayo Fukushima"><meta name="DC.Contributor" content="Rüdiger Kaspera"><meta name="DC.Contributor" content="Joshua C. Bis"><meta name="DC.Contributor" content="Nicole L. Glazer"><meta name="DC.Contributor" content="Guo Li"><meta name="DC.Contributor" content="Thomas R. Austin"><meta name="DC.Contributor" content="Kent D. Taylor"><meta name="DC.Contributor" content="Jerome I. Rotter"><meta name="DC.Contributor" content="Cashell E. Jaquish"><meta name="DC.Contributor" content="Pui-Yan Kwok"><meta name="DC.Contributor" content="Russell P. Tracy"><meta name="DC.Contributor" content="Bruce M. Psaty"><meta name="DC.Date" content="2011 May"><meta name="DC.Identifier" content="10.1097/FPC.0b013e328343dd7d"><meta name="DC.Language" content="en"><meta property="og:title" content="Cerivastatin, Genetic Variants, and the Risk of Rhabdomyolysis"><meta property="og:type" content="article"><meta property="og:description" content="The withdrawal of cerivastatin involved an uncommon but serious adverse reaction, rhabdomyolysis. The bimodal response--rhabdomyolysis in a small proportion of users-- points to genetic factors as a potential cause. We conducted a case-control study to ..."><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076530/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><meta name="ncbi_feature" content="associated_data"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css"><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/'"><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css"><script type="text/javascript" src="/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><meta name="cited_in_systematic_reviews" content=""><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC3076530/epub/"><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC3076530/pdf/nihms-265998.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="CE8CAAFDDD5214A1000000000463029E.m_8">
<meta name="referrer" content="origin-when-cross-origin"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css"><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print"><script async="1" src="https://www.google-analytics.com/analytics.js"></script><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1px; bottom: 2px; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/jax/output/HTML-CSS/config.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/jax/input/MathML/config.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/jax/output/NativeMML/config.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/mml2jax.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/MathEvents.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/MathZoom.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/MathMenu.js?rev=2.6.1"></script><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/mathjax/2.6.1/extensions/toMathML.js?rev=2.6.1"></script></head>
    <body class="article" id="ui-ncbiexternallink-4"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi" style="top: -0.4em;"><iframe src="https://eutils.ncbi.nlm.nih.gov/entrez/eutils/emyncbi.fcgi?cmd=htmlportal&amp;currenturl=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3076530%2F" style="border:none; height:2.5em; width:40em;" scrolling="no"></iframe></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="jig-ncbiclearbutton-wrap ui-ncbiclearbutton-wrap box-shadow"><input name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'yes'" aria-haspopup="true" aria-autocomplete="list" role="textbox" type="text"><a class="reset" href="#" style="visibility: hidden;"><img src="/core/jig/1.14.8/img/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=hhs%20author%20manuscript[filter]" class="navlink">HHS Author Manuscripts</a></li><li class="accid">PMC3076530</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt="Logo of nihpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,57,255,75" alt="About Author manuscripts" title="About Author manuscripts" href="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref="https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html"><area shape="rect" coords="256,57,500,75" alt="Submit a manuscript" title="Submit a manuscript" href="https://www.nihms.nih.gov/" ref="reftype=publisher&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"><area shape="rect" coords="0,0,499,74" alt="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" title="HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;" href="https://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref="reftype=publisher&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'" id="ui-ncbiinpagenav-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><span role="menubar"><a href="#" role="menuitem" aria-expanded="false" aria-haspopup="true">Pharmacogenet Genomics</a></span>. Author manuscript; available in PMC 2012 May 1.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=21386754" target="pmc_ext" ref="reftype=publisher&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access"><span class="cit">Pharmacogenet Genomics. 2011 May; 21(5): 280–288. </span></a></div> <span class="doi">doi:&nbsp;<a href="//dx.doi.org/10.1097%2FFPC.0b013e328343dd7d" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1097/FPC.0b013e328343dd7d</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3076530</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">NIHMSID: </span><span>NIHMS265998</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/21386754">21386754</a></div></div></div></div><h1 class="content-title">Cerivastatin, Genetic Variants, and the Risk of Rhabdomyolysis</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Marciante%20KD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Kristin D. Marciante</a>, PhD, <a href="/pubmed/?term=Durda%20JP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Jon P. Durda</a>, <a href="/pubmed/?term=Heckbert%20SR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Susan R. Heckbert</a>, MD, PhD, <a href="/pubmed/?term=Lumley%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Thomas Lumley</a>, PhD, <a href="/pubmed/?term=Rice%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Ken Rice</a>, PhD, <a href="/pubmed/?term=McKnight%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Barbara McKnight</a>, PhD, <a href="/pubmed/?term=Totah%20RA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Rheem A. Totah</a>, PhD, <a href="/pubmed/?term=Tamraz%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Bani Tamraz</a>, PharmD, <a href="/pubmed/?term=Kroetz%20DL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Deanna L. Kroetz</a>, PhD, <a href="/pubmed/?term=Fukushima%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Hisayo Fukushima</a>, PhD, <a href="/pubmed/?term=Kaspera%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Rüdiger Kaspera</a>, PhD, <a href="/pubmed/?term=Bis%20JC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Joshua C. Bis</a>, PhD, <a href="/pubmed/?term=Glazer%20NL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Nicole L. Glazer</a>, PhD, <a href="/pubmed/?term=Li%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Guo Li</a>, MS, <a href="/pubmed/?term=Austin%20TR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Thomas R. Austin</a>, <a href="/pubmed/?term=Taylor%20KD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Kent D. Taylor</a>, PhD, <a href="/pubmed/?term=Rotter%20JI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Jerome I. Rotter</a>, MD, <a href="/pubmed/?term=Jaquish%20CE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Cashell E. Jaquish</a>, PhD, <a href="/pubmed/?term=Kwok%20PY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Pui-Yan Kwok</a>, MD, PhD, <a href="/pubmed/?term=Tracy%20RP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Russell P. Tracy</a>, PhD, and  <a href="/pubmed/?term=Psaty%20BM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=21386754">Bruce M. Psaty</a>, MD, PhD</div><div style="display:none" class="contrib-group aff-tip"></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140254445728192_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140254445728192_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140254445728192_ai" style="display:none"><div class="fm-affl" id="A1" lang="en">Cardiovascular Health Research Unit (Marciante, Heckbert, Lumley, Rice, McKnight, Bis, Glazer, Psaty, Li and Austin), Departments of Medicine (Marciante, Bis, Glazer, Psaty and Li), Epidemiology (Heckbert and Psaty), Biostatistics (Lumley, Rice, and McKnight), Medicinal Chemistry (Totah and Kaspera), and Health Services (Psaty), University of Washington, Seattle, WA; Group Health Research Institute, Group Health Cooperative, Seattle, WA (Heckbert and Psaty); Departments of Pathology (Tracy and Durda) and Biochemistry (Tracy), University of Vermont, Colchester, Vermont; Department of Dermatology (Kwok), Cardiovascular Research Institute (Kwok and Tamraz), and Department of Bioengineering and Therapeutic Sciences (Kroetz and Fukushima), University of California, San Francisco, San Francisco, California; Whitman College, Walla Walla, WA (Austin); Medical Genetics Research Institute, Cedars-Sinai Medical Center, Los Angeles CA (Rotter and Taylor); Division of Cardiovascular Sciences, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda MD (Jaquish)</div><div id="CR1"><strong>Correspondence/Reprint Requests:</strong> Kristin D. Marciante, PhD Cardiovascular Health Research Unit 1730 Minor Ave. Suite 1360 Seattle, WA 98101 206-287-2777 (phone) 206-287-2662 (fax) <a href="mailto:dev@null" data-email="ude.wu@tnaicram" class="oemail">ude.wu@tnaicram</a></div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm140254445728192_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>The publisher's final edited version of this article is available  at <a href="/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=21386754" target="pmc_ext" ref="reftype=publisher&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access">Pharmacogenet Genomics</a></div><div>See other articles in PMC that <a href="/pmc/articles/PMC3076530/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 class="ui-helper-clearfix" id="ui-ncbiinpagenav-heading-3">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Supplementary Material.</strong></div><div><a href="/pmc/articles/PMC3076530/bin/NIHMS265998-supplement-Supplementary_Material.doc" data-ga-action="click_feat_suppl">NIHMS265998-supplement-Supplementary_Material.doc</a><span style="color:gray"> (595K)</span></div><div class="small guid">GUID:&nbsp;1A6335D5-3BDF-491E-9D84-BC5F3DD8ABCE</div></div></dd></dl></div><div id="idm140254466948512" class="tsec sec" lang="en"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140254466948512title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3 id="S1title">Objective</h3><p id="P1" class="p p-first-last">The withdrawal of cerivastatin involved an uncommon but serious adverse reaction, rhabdomyolysis. The bimodal response--rhabdomyolysis in a small proportion of users-- points to genetic factors as a potential cause. We conducted a case-control study to evaluate genetic markers for cerivastatin-associated rhabdomyolysis.</p></div><div id="S2" class="sec"><h3 id="S2title">Methods</h3><p id="P2" class="p p-first-last">The study had two components: a candidate gene study to evaluate variants in <em>CYP2C8, UGT1A1, UGT1A3</em>, and <em>SLCO1B1</em>; and a genome-wide association (GWA) study to identify risk factors in other regions of the genome. 185 rhabdomyolysis cases were frequency matched to statin-using controls from the Cardiovascular Health Study (n=374) and the Heart and Vascular Health Study (n=358). Validation relied on functional studies.</p></div><div id="S3" class="sec"><h3 id="S3title">Results</h3><p id="P3" class="p p-first-last">Permutation test results suggested an association between cerivastatin-associated rhabdomyolysis and variants in <em>SLCO1B1</em> (p = 0.002), but not variants in <em>CYP2C8</em> (p = 0.073) or the <em>UGTs</em> (p = 0.523). An additional copy of the minor allele of <em>SLCO1B1</em> rs4149056 (p.Val174Ala) was associated with the risk of rhabdomyolysis (OR: 1.89, 95% CI: 1.40 to 2.56). In transfected cells, this variant reduced cerivastatin transport by 40% compared with the reference transporter (p &lt; 0.001). The GWA identified an intronic variant (rs2819742) in the ryanodine receptor 2 gene (<em>RYR2</em>) as significant (p=1.74E-07). An additional copy of the minor allele of the <em>RYR2</em> variant was associated with a reduced risk of rhabdomyolysis (OR: 0.48; 95% CI: 0.36 to 0.63).</p></div><div id="S4" class="sec sec-last"><h3 id="S4title">Conclusion</h3><p id="P4" class="p p-first-last">We identified modest genetic risk factors for an extreme response to cerivastatin. Disabling genetic variants in the candidate genes were not responsible for the bimodal response to cerivastatin.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Genetics, drugs, epidemiology, rhabdomyolysis</span></div></div><div id="S5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S5title">Introduction</h2><p id="P5" class="p p-first">High-profile drug withdrawals have often involved serious adverse reactions such as liver failure in troglitazone users or heart-valve damage in dexfenfluramine users [<a href="#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102821">1</a>, <a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102801">2</a>]. The occurrence of an extreme adverse reaction to a new drug sets a small number of people apart from the rest of users who have few if any side effects. Although the cause may be environmental, such as a drug-drug interaction, the bimodal response points to genetic factors as a potential cause [<a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102802">3</a>, <a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102799">4</a>].</p><p id="P6">Cerivastatin, an HMG-CoA reductase inhibitor (statin), was withdrawn from the market in 2001 because of a pronounced increase in the risk of rhabdomyolysis, which causes muscle pain and weakness and sometimes renal failure and death [<a href="#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102792">5</a>]. About half of the rhabdomyolysis cases reported to the FDA occurred in subjects who had taken both cerivastatin and the fibrate, gemfibrozil [<a href="#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102816">5</a>, <a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102807">6</a>]. In one study, combined cerivastatin-fibrate use was associated with a 1411 fold higher risk of rhabdomyolysis than the use of other statin monotherapies [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102800">7</a>]. In pharmacokinetic studies, gemfibrozil inhibited the major disposal pathways for cerivastatin, not only the drug-metabolizing enzymes, CYP2C8, UGT1A1, and UGT1A3 [<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102820">8</a>,<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102809">9</a>], but also the transporter, OATP1B1, responsible for uptake of cerivastatin into hepatic cells [<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102794">10</a>].</p><p id="P7" class="p p-last">The pronounced effect of gemfibrozil on these candidate gene products suggested that genetic variants, including rare ones, might play a major role in this adverse effect, especially in subjects who did not use gemfibrozil. We performed a case-control study to evaluate common, novel, and rare genetic risk factors for cerivastatin-associated rhabdomyolysis. This study of cerivastatin-associated rhabdomyolysis had two components: (1) a candidate gene study to evaluate the association of variants in <em>CYP2C8, UGT1A1, UGT1A3</em>, and <em>SLCO1B1</em> (the gene that encodes OATP1B1); and (2) a genome-wide association (GWA) study to identify risk factors in other regions of the genome. The primary purpose of the study was to test the hypothesis that common or rare disabling variants in the genes encoding the metabolizing enzymes or the transporter would have a gemfibrozil-like effect on the incidence of this severe idiosyncratic adverse drug reaction.</p></div><div id="S6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S6title">Methods</h2><div id="S7" class="sec sec-first"><h3 id="S7title">Setting</h3><p id="P8" class="p p-first-last">Cases were recruited through attorneys who had represented cerivastatin users with rhabdomyolysis and had settled their cases with the manufacturer. Attorneys were offered reimbursement for their recruitment efforts. Because the identification of the optimal control group, a random sample of cerivastatin users who did not develop rhabdomyolysis, was infeasible, we selected as controls statin-using subjects from two ongoing population-based studies: the Heart and Vascular Health Study (HVH) [<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102838">11</a>-<a href="#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102836">13</a>] and the Cardiovascular Health Study (CHS) (see <a href="#SD1" rid="SD1" class=" supplementary-material">Methods, Supplemental Digital Content 1</a>, Setting) [<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102823">14</a>]. The recruitment of the case subjects and the use of the CHS subjects were approved by the University of Washington Institutional Review Board. The Group Health Human Subjects Review Committee approved the use of the HVH study subjects. Subjects provided written informed consent.</p></div><div id="S8" class="sec"><h3 id="S8title">Case Definition, Recruitment, and Data Collection</h3><p id="P9" class="p p-first-last">Eighteen attorneys screened their clients for interest in the study and provided contact information for potential participants to study coordinators (See <a href="#SD1" rid="SD1" class=" supplementary-material">Figure 1, Supplemental Digital Content 1</a>, Rhabdomyolysis case subject recruitment). Case subjects who participated in the study were demographically similar to those who did not (see <a href="#SD1" rid="SD1" class=" supplementary-material">Table 1, Supplemental Digital Content 1</a>, Characteristics of case subjects who did and did not participate in the study). For consenting cases, study staff conducted a telephone interview and obtained copies of medical records from attorneys, doctors, and hospitals. Trained abstracters used the medical records to validate the rhabdomyolysis event and collect information about participants' medical history. Definite rhabdomyolysis was defined as muscle pain or weakness associated with creatine kinase levels greater than 10 times the upper limit of laboratory normal. Six subjects who would likely have been definite cases had their medical history been complete were included in the primary analysis. Subjects collected buccal cell DNA using a swish and spit mouthwash kit. Information on race was obtained from the telephone interview, medical records, and attorneys.</p></div><div id="S9" class="sec"><h3 id="S9title">Selection of Controls</h3><p id="P10" class="p p-first-last">CHS participants selected as controls reported using a statin at an annual study visit between 1989 and 2002. They were frequency matched to the rhabdomyolysis cases by sex at a ratio of 2 controls per case. CHS controls were free of inpatient diagnostic codes for rhabdomyolysis in the year before their qualifying statin-use visit (n=0 excluded) [<a href="#R15" rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102834">15</a>]. HVH controls used a statin at the time they were selected as a control for the HVH studies (between 1995 and 2005). They were frequency matched to the rhabdomyolysis cases by sex and age by decade at a ratio of 2 to 1 (See <a href="#SD1" rid="SD1" class=" supplementary-material">Methods, Supplemental Digital Content 1</a>, Selection of controls). HVH controls with a creatine kinase value &gt;10 times the upper limit of laboratory normal in the year before their qualifying statin-use date were excluded (n=2).</p></div><div id="S10" class="sec"><h3 id="S10title">Selection of Single Nucleotide Polymorphisms in Candidate Gene Analysis</h3><p id="P11" class="p p-first-last">To identify novel genetic variants in the four candidate genes, we re-sequenced the DNA from the first 126 rhabdomyolysis cases recruited (See <a href="#SD1" rid="SD1" class=" supplementary-material">Methods and Tables 2-4, Supplemental Digital Content 1</a>, PCR and sequencing methods, and primers and conditions). Re-sequenced regions included exons, intron-exon boundaries, the promoter and the untranslated regions of each gene. The resequencing effort identified 45 novel variants, which were submitted to dbSNP. To identify other variants of interest, we used HapMap CEU data and publicly available resequencing data to select two other sets of single nucleotide polymorphisms (SNPs): 1) tagSNPs that captured information on common variants (minor allele frequency &gt;= 2.5%) [<a href="#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102810">16</a>]; and 2) SNPs predicted to be functional (F-SNPs) by the bioinformatics program F-SNP (<a href="http://compbio.cs.queensu.ca/F-SNP/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://compbio.cs.queensu.ca/F-SNP/</a>).</p></div><div id="S11" class="sec"><h3 id="S11title"><em>In vitro</em> functional data for key <em>SLCO1B1</em> variant</h3><p id="P12" class="p p-first-last">The functional effect of the <em>SLCO1B1</em> variant rs4149056 (c.521T&gt;C; p.Val174Ala) on cerivastatin uptake was measured in stable HEK293 (human embryonic kidney epithelial) cells expressing the reference and variant transporter (See <a href="#SD1" rid="SD1" class=" supplementary-material">Methods, Supplemental Digital Content 1</a>, in vitro functional assessment of <em>SLCO1B1 rs4149056</em> variant).</p></div><div id="S12" class="sec"><h3 id="S12title">Genome-Wide Association Screen</h3><p id="P13" class="p p-first-last">We used the Illumina Infinium 370 CNV chip to obtain GWA data on the cases (See <a href="#SD1" rid="SD1" class=" supplementary-material">Methods, Supplemental Digital Content 1</a>, Genome-wide association screen: subjects and selection of SNPs). We used existing GWA data on statin-using CHS controls who had been genotyped on the same Illumina platform. (See <a href="#SD1" rid="SD1" class=" supplementary-material">Table 5, Supplemental Digital Content 1</a>, Characteristics of GWA screen study subjects). Because the genotyping was done at two different times in two different laboratories (See <a href="#SD1" rid="SD1" class=" supplementary-material">Table 5, Supplemental Digital Content 1</a>, Characteristics of GWA screen study subjects), we re-genotyped GWA high signal markers in the rhabdomyolysis cases and controls selected for the candidate gene work. The most significant SNP from each of the 6 high-signal loci (SNPs with p-values &lt;1E-05) (<a href="/pmc/articles/PMC3076530/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a>), was re-genotyped to exclude drift, batch, or laboratory effects.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC3076530/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140254466025472" class="figure"><a href="/pmc/articles/PMC3076530/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3076530_nihms-265998-f0001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms-265998-f0001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3076530/bin/nihms-265998-f0001.jpg"></a></div><div id="largeobj_idm140254466025472" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3076530/figure/F1/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC3076530/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p3">Stripe plot of genome-wide association screen among rhabdomyolysis cases (N=175) and CHS statin-using controls with GWA data (n=645). Directly genotyped SNPs with minor allele frequencies ≥ 5% = 292,461. The analysis was adjusted for age and sex. Six loci with minor allele frequencies ≥5% fell below the p&lt;1E-05 threshold for re-genotyping.</p></div></div></div></div><div id="S13" class="sec"><h3 id="S13title">Genotyping in cases and controls</h3><p id="P14" class="p p-first-last">Re-genotyped SNPs included (1) the novel SNPs discovered by resequencing, and (2) the high-signal markers identified by the GWA screen. The other sources of SNPs for genotyping were the candidate gene tagSNPs and F-SNPs (See <a href="#SD1" rid="SD1" class=" supplementary-material">Table 6, Supplemental Digital Content 1</a>, SNPS selected for genotyping by gene, type, platform, and outcome). Genotyping methods included an Illumina Goldengate custom panel and, for failed or undesignable SNPs, the Taqman 5' nuclease discrimination assay. SNPs with poor Taqman results underwent pyrosequencing on the PyroMark Q96MD platform. For each SNP, all cases and controls were genotyped on the same platform (See <a href="#SD1" rid="SD1" class=" supplementary-material">Methods, Supplemental Digital Content 1</a>, Re-genotyping in cases and controls). SNPs were in Hardy-Weinberg equilibrium in controls of European descent, except for two <em>UGT</em> F-SNPs, rs17862867 and rs6431625.</p></div><div id="S14" class="sec sec-last"><h3 id="S14title">Statistical Analysis</h3><p id="P15" class="p p-first-last">We pooled the CHS and HVH controls for the analysis. Rare functional SNPs (&lt;1% minor allele frequency) within each gene were collapsed to assess the association between case status and having at least one rare variant [<a href="#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102830">17</a>]. Rare (&lt;1% minor allele frequency) novel SNPs within each gene were also collapsed. All other SNPs were modeled additively. Logistic regression models were fit using robust standard errors and were adjusted for age at statin use, sex, and race (See <a href="#SD1" rid="SD1" class=" supplementary-material">Methods, Supplemental Digital Content 1</a>, Statistical analysis). We used a permutation test to provide a gene level p-value that accounted for the multiple SNPs tested within each candidate gene [<a href="#R18" rid="R18" class=" bibr popnode">18</a>]. <em>UGT1A1</em> and <em>UGT1A3,</em> which share exons 2-5, were analyzed together. A candidate gene was considered significant if the permutation p-value was &lt;0.05. High signal GWA markers were considered significant if their p-value after re-genotyping was &lt; 4E-07 (1/2.5million tests). Sensitivity analyses included an analysis restricted to controls and definite cases and an analysis restricted to subjects who did not use gemfibrozil.</p></div></div><div id="S15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S15title">Results</h2><div id="S16" class="sec sec-first"><h3 id="S16title">Subjects</h3><p id="P16" class="p p-first">Among the 215 eligible rhabdomyolysis cases recruited to the study, 27 were deceased, 2 did not have usable DNA, and 1 failed genotyping (See <a href="#SD1" rid="SD1" class=" supplementary-material">Figure 1, Supplemental Digital Content 1</a>, Rhabdomyolysis case subject recruitment). Most cases experienced both muscle pain and weakness; creatine kinase values indicated significant muscle damage; 81.6% were hospitalized; and 21.6% had renal failure (top part of <a href="/pmc/articles/PMC3076530/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). The prescribed daily dose of cerivastatin was high; approved doses ranged between 0.2mg and 0.8mg.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p5">Characteristics of Rhabdomyolysis Cases and Controls</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140254464834736" class="xtable"><table frame="above" rules="groups" class="rendered small default_table"><thead><tr><th colspan="2" rowspan="1" valign="top" align="center">Rhabdomyolysis Case Characteristics (N=185)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">Muscle pain, %</td><td rowspan="1" colspan="1" valign="top" align="left">91.9</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Muscle weakness, %</td><td rowspan="1" colspan="1" valign="top" align="left">84.9</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Creatine kinase<sup>*</sup> U/L, mean (std. dev)</td><td rowspan="1" colspan="1" valign="top" align="left">55,166.2 (78,373.9)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Creatine kinase<sup>*</sup> U/L, median (range)</td><td rowspan="1" colspan="1" valign="top" align="left">30,200 (1341 – 720,000)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Hospitalized rhabdomyolysis, %</td><td rowspan="1" colspan="1" valign="top" align="left">81.6</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Days of hospitalization, mean (std. dev.)</td><td rowspan="1" colspan="1" valign="top" align="left">6.7 (6.2)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Creatinine<sup>†</sup> μmol/L, mean (std. dev.)</td><td rowspan="1" colspan="1" valign="top" align="left">176.8 (212.2)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Creatinine<sup>†</sup> μmol/L, median (range)</td><td rowspan="1" colspan="1" valign="top" align="left">88.4 (17.7 – 1211.1)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Renal Failure, %</td><td rowspan="1" colspan="1" valign="top" align="left">21.6</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Hemodialysis, %</td><td rowspan="1" colspan="1" valign="top" align="left">7.0</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Cerivastatin dose<sup>‡</sup> mg, mean (std. dev.)</td><td rowspan="1" colspan="1" valign="top" align="left">0.6 (0.2)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Cerivastatin dose<sup>‡</sup> mg, median (range)</td><td rowspan="1" colspan="1" valign="top" align="left">0.8 (0.2 – 1.6)</td></tr></tbody></table></div><div id="largeobj_idm140254464834736" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3076530/table/T1/?report=objectonly">Open in a separate window</a></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140254448209808" class="xtable"><table frame="below" rules="groups" class="rendered small default_table"><thead><tr><th colspan="4" rowspan="1" valign="top" align="center">Case and Control Characteristics</th></tr><tr><th colspan="4" rowspan="1" valign="top" align="left"><hr></th></tr><tr><th rowspan="1" colspan="1" valign="top" align="left"></th><th rowspan="1" colspan="1" valign="top" align="left">Rhabdomyolysis Cases</th><th rowspan="1" colspan="1" valign="top" align="left">CHS<sup>§</sup> controls</th><th rowspan="1" colspan="1" valign="top" align="left">HVH<sup>∥</sup> controls</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="top" align="left">Subjects with any genotype data (N=917)</td><td rowspan="1" colspan="1" valign="top" align="left">N=185</td><td rowspan="1" colspan="1" valign="top" align="left">N=374</td><td rowspan="1" colspan="1" valign="top" align="left">N=358</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Female, %</td><td rowspan="1" colspan="1" valign="top" align="left">61.1</td><td rowspan="1" colspan="1" valign="top" align="left">61.0</td><td rowspan="1" colspan="1" valign="top" align="left">48.0</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Age, mean (std)</td><td rowspan="1" colspan="1" valign="top" align="left">63.5 (10.6)</td><td rowspan="1" colspan="1" valign="top" align="left">73.6 (4.1)</td><td rowspan="1" colspan="1" valign="top" align="left">64.5 (9.4)</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Age, range</td><td rowspan="1" colspan="1" valign="top" align="left">34-89</td><td rowspan="1" colspan="1" valign="top" align="left">65-89</td><td rowspan="1" colspan="1" valign="top" align="left">36-89</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">European descent, %</td><td rowspan="1" colspan="1" valign="top" align="left">90.8</td><td rowspan="1" colspan="1" valign="top" align="left">84.5</td><td rowspan="1" colspan="1" valign="top" align="left">89.4</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Location</td><td rowspan="1" colspan="1" valign="top" align="left">US, Canada</td><td rowspan="1" colspan="1" valign="top" align="left">CA, MD, PA, NC</td><td rowspan="1" colspan="1" valign="top" align="left">Western WA</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Statin user<sup>#</sup>, %</td><td rowspan="1" colspan="1" valign="top" align="left">100.0</td><td rowspan="1" colspan="1" valign="top" align="left">100.0</td><td rowspan="1" colspan="1" valign="top" align="left">100.0</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Gemfibrozil user, %</td><td rowspan="1" colspan="1" valign="top" align="left">63.8</td><td rowspan="1" colspan="1" valign="top" align="left">0.0</td><td rowspan="1" colspan="1" valign="top" align="left">1.4</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Subjects with Illumina genotype data (n=910)</td><td rowspan="1" colspan="1" valign="top" align="left">N=181</td><td rowspan="1" colspan="1" valign="top" align="left">N=372</td><td rowspan="1" colspan="1" valign="top" align="left">N=357</td></tr><tr><td rowspan="1" colspan="1" valign="top" align="left">Subjects with Taqman genotype data (n=904)</td><td rowspan="1" colspan="1" valign="top" align="left">N=183</td><td rowspan="1" colspan="1" valign="top" align="left">N=366</td><td rowspan="1" colspan="1" valign="top" align="left">N=355</td></tr></tbody></table></div><div id="largeobj_idm140254448209808" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3076530/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN1"><sup>*</sup>Eight values recorded as ‘out of range’ were not used in this summary. Upper limits of normal ranged from 115 to 400 U/L.</div><div id="TFN2"><sup>†</sup>Upper limits of normal for creatinine ranged from 88.4 to 150.3.</div><div id="TFN3"><sup>‡</sup>Dose information was missing for 33 case subjects</div><div id="TFN4"><sup>§</sup>Cardiovascular Health Study</div><div id="TFN5"><sup>∥</sup>Heart and Vascular Health Study</div><div id="TFN6"><sup>#</sup>Cases used cerivastatin. CHS Controls used lovastatin (43.9%), simvastatin (18.7%), atorvastatin (12.6%), fluvastatin (5.6%), pravastatin (18.5%), or cerivastatin (1.1%). HVH controls used lovastatin (25.7%), simvastatin (69.0%), atorvastatin (3.9%), or pravastatin (1.4%).</div></div></div><p id="P17" class="p p-last">Genotype data were available on 185 cases, 374 controls from CHS, and 358 controls from HVH (bottom part of <a href="/pmc/articles/PMC3076530/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>). The cases were mostly female (61%) and ranged widely in age (34-89). The CHS controls were mostly women (61%), were elderly (mean age 74 years), and resided in four US communities. The HVH controls, from western Washington State, included fewer female statin users, but were similar in age to the rhabdomyolysis cases. Cases used cerivastatin, and 64% were concomitant users of gemfibrozil. The CHS and HVH controls used lovastatin, simvastatin, atorvastatin, fluvastatin, pravastatin or cerivastatin. The distribution of statin use reflects the Group Health formulary preferences for HVH controls and the time period over which the CHS controls were sampled. Few controls used gemfibrozil.</p></div><div id="S17" class="sec"><h3 id="S17title">Candidate-gene results</h3><p id="P18" class="p p-first">Permutation test results suggested strong evidence for an association between cerivastatin-associated rhabdomyolysis and variants in <em>SLCO1B1</em> (p = 0.002), but not <em>CYP2C8</em> (p = 0.073) or the <em>UGTs</em> (p = 0.523). <a href="/pmc/articles/PMC3076530/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a> summarizes the key results for <em>SLCO1B1</em> in the top section and for <em>CYP2C8</em> in the bottom section. The entire and largely null set of results for <em>SLCO1B1</em>, <em>CYP2C8,</em> and for the <em>UGT</em> candidate gene complex are described in <a href="#SD1" rid="SD1" class=" supplementary-material">Results and Tables 7, 8, and 9, Supplemental Digital Content 1</a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p6">Selected findings for the candidate genes <em>SLCO1B1</em> and <em>CYP2C8</em>. Models adjusted for age at statin use, sex, and race.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140254448384304" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="left"></th><th rowspan="1" colspan="1" valign="middle" align="center">Modeled Allele</th><th rowspan="1" colspan="1" valign="middle" align="center">Minor Allele<br> Frequency<br> (Controls)<br> N=732</th><th rowspan="1" colspan="1" valign="middle" align="center">Minor Allele<br> Frequency<br> (Cases)<br> N=185</th><th rowspan="1" colspan="1" valign="middle" align="center">Odds ratio (95%<br> confidence interval)</th><th rowspan="1" colspan="1" valign="middle" align="right">p-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<strong><em>SLCO1B1</em></strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="right"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<em>TagSNPs<sup>*</sup></em>
</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="right"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">rs4149033 (G/A)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies A allele</td><td rowspan="1" colspan="1" valign="middle" align="center">0.210</td><td rowspan="1" colspan="1" valign="middle" align="center">0.270</td><td rowspan="1" colspan="1" valign="middle" align="center">1.41 ( 1.06 to 1.87)</td><td rowspan="1" colspan="1" valign="middle" align="right">0.02</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<em>FSNPs</em>
<sup>†</sup>
</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="right"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">rs4149056 (G/A)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies A allele</td><td rowspan="1" colspan="1" valign="middle" align="center">0.140</td><td rowspan="1" colspan="1" valign="middle" align="center">0.240</td><td rowspan="1" colspan="1" valign="middle" align="center">1.89 ( 1.40 to 2.56)</td><td rowspan="1" colspan="1" valign="middle" align="right">3.62E-05</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td colspan="3" rowspan="1" valign="middle" align="center">Gene-wide permutation test result p=0.002</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<strong>CYP2C8</strong>
</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="right"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<em>F-SNPs</em>
<sup>†</sup>
</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="right"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">rs1058930 (<sup>*</sup>4 allele) (C/G)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies G allele</td><td rowspan="1" colspan="1" valign="middle" align="center">0.054</td><td rowspan="1" colspan="1" valign="middle" align="center">0.041</td><td rowspan="1" colspan="1" valign="middle" align="center">0.67 ( 0.36 to 1.26)</td><td rowspan="1" colspan="1" valign="middle" align="right">0.22</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">rs11572080 (<sup>*</sup>3 allele) (C/T)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies T allele</td><td rowspan="1" colspan="1" valign="middle" align="center">0.097</td><td rowspan="1" colspan="1" valign="middle" align="center">0.087</td><td rowspan="1" colspan="1" valign="middle" align="center">0.73 ( 0.47 to 1.13)</td><td rowspan="1" colspan="1" valign="middle" align="right">0.16</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">rs11572103 (<sup>*</sup>2 allele) (A/T)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies T allele</td><td rowspan="1" colspan="1" valign="middle" align="center">0.013</td><td rowspan="1" colspan="1" valign="middle" align="center">0.006</td><td rowspan="1" colspan="1" valign="middle" align="center">0.68 ( 0.15 to 3.12)</td><td rowspan="1" colspan="1" valign="middle" align="right">0.62</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">rs10509681 (<sup>*</sup>3 allele) (A/G)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies G allele</td><td rowspan="1" colspan="1" valign="middle" align="center">0.100</td><td rowspan="1" colspan="1" valign="middle" align="center">0.081</td><td rowspan="1" colspan="1" valign="middle" align="center">0.64 ( 0.42 to 0.98)</td><td rowspan="1" colspan="1" valign="middle" align="right">0.04</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td colspan="3" rowspan="1" valign="middle" align="center">Gene-wide permutation test result p=0.07</td></tr></tbody></table></div><div id="largeobj_idm140254448384304" class="largeobj-link align_right" style=""><a target="object" href="/pmc/articles/PMC3076530/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN7"><sup>*</sup>Single nucleotide polymorphism</div><div id="TFN8"><sup>†</sup>Functional single nucleotide polymorphism</div></div></div><p id="P19">For <em>SLCO1B1</em> (<a href="/pmc/articles/PMC3076530/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>), the primary finding involved the functional, nonsynonymous SNP rs4149056. An additional copy of its minor allele was associated with an increased risk of rhabdomyolysis (OR: 1.89, 95% CI: 1.40 to 2.56). Carriers of two copies of the minor allele had a four-fold higher risk of rhabdomyolysis compared with carriers of two copies of the major allele (OR: 4.34; 95% CI: 1.86 to 10.10).</p><p id="P20">In functional studies, transport of cerivastatin into the transfected reference cells was 2.7-fold higher than the empty vector cells (1.01 ± 0.12 vs. 0.38 ± 0.12; p &lt; 0.001), indicating the presence of OATP1B1-specific transport (<a href="/pmc/articles/PMC3076530/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>). Compared with the reference transporter, the transporter with the <em>SLCO1B1</em> rs4149056 variant showed a 40% reduction in cerivastatin uptake (0.61 ± 0.15 vs. 1.01 ± 0.12; p &lt; 0.001).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC3076530/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--></a><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140254462937008" class="figure"><a href="/pmc/articles/PMC3076530/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"></a><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3076530_nihms-265998-f0002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.
Object name is nihms-265998-f0002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3076530/bin/nihms-265998-f0002.jpg"></a></div><div id="largeobj_idm140254462937008" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3076530/figure/F2/?report=objectonly">Open in a separate window</a></div><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC3076530/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p4">Intracellular accumulation of CER in HEK293 cells expressing Empty Vector, OATP1B1 Reference and the p.Val174Ala variant of OATP1B1. All values are expressed relative to OATP1B1 Reference and are shown as mean ± S.D of 11 replicates measured in three separate experiments. Significant differences were detected by one-way ANOVA followed by Bonferroni correction for multiple testing and post hoc multiple comparison testing: Reference and p.Val174Ala variant (P&lt;0.001), Reference and Empty Vector (P&lt;0.001), Empty Vector and p.Val174Ala variant (P&lt;0.01).</p></div></div></div><p id="P21">A second potential <em>SLCO1B1</em> signal was the intronic tagSNP, rs4149033 (OR = 1.41; 95% CI = 1.06 to 1.87). In an analysis that excluded the gemfibrozil users, the association was especially strong (OR: 2.17; 95% CI: 1.47 to 3.21; p-value=0.00011). Rs4149033 was weakly correlated with rs4149056 (r<sup>2</sup>=0.19). The associations remained when both rs4149033 and rs4149056 were included in a model limited to subjects who did not use gemfibrozil (p=0.029 and p=0.012, respectively).</p><p id="P22">The nonsynonymous variant, rs2306283 (c.388A&gt;G, p.Asn130Asp), which often co-exists with rs4149056 was not associated with an increased risk of rhabdomyolysis (OR: 0.96; 95% CI: 0.75 to 1.24; p-value 0.78). The results for rs2306283 are shown in <a href="#SD1" rid="SD1" class=" supplementary-material">Table 7 of the supplementary material</a>.</p><p id="P23" class="p p-last">Although the permutation test was not significant (p=0.073) for <em>CYP2C8</em> (bottom of <a href="/pmc/articles/PMC3076530/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>) and (<a href="#SD1" rid="SD1" class=" supplementary-material">Table 8, Supplemental Digital Content 1</a>, <em>CYP2C8</em> tagSNP, FSNP and novel SNP analysis), three tag SNPs and one F-SNP had uncorrected p-values &lt;0.05. The well-characterized <em>CYP2C8*2</em>, <em>*3</em>, and <em>*4</em> alleles were less common in cases than controls, though not significantly so. Results were similar when analyses were limited to definite cases, and non-users of gemfibrozil.</p></div><div id="S18" class="sec"><h3 id="S18title">GWA results</h3><p id="P24" class="p p-first-last">The 6 high-signal markers identified by GWA analyses were re-genotyped in the cases and both HVH and CHS controls (<a href="/pmc/articles/PMC3076530/table/T3/" target="table" class="fig-table-link figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). After re-genotyping, one intronic variant (rs2819742) in the ryanodine receptor 2 gene (<em>RYR2</em>) was significant at the <em>a priori</em> p-value threshold of 4E-07 (p=1.74E-07). An additional copy of the minor allele of the <em>RYR2</em> variant was associated with a reduced risk of cerivastatin-associated rhabdomyolysis (OR: 0.48; 95% CI: 0.36 to 0.63). Carriers of two copies of the minor allele had a smaller risk of rhabdomyolysis than carriers of two copies of the major allele (OR: 0.24; 95% CI: 0.13 to 0.44). The <em>SLCO1B1</em> variant rs4149056 was not genotyped in the GWA, but a SNP in LD with it (rs4363657, r<sup>2</sup> = 0.79) had similar results (OR: 2.30; p-value=1.62E-05) to those observed for rs4149056 in the candidate gene work.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="__p7">Results from re-genotyping high signal markers from the GWA<sup>*</sup> screen on the TaqMan platform in candidate gene subjects. Models adjusted for age at statin use, sex, and race.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140254458922880" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="center">Gene</th><th rowspan="1" colspan="1" valign="middle" align="center">SNP<sup>†</sup></th><th rowspan="1" colspan="1" valign="middle" align="center">Modeled Allele</th><th rowspan="1" colspan="1" valign="middle" align="center">p-value<br> from<br> GWA<br> screen</th><th rowspan="1" colspan="1" valign="middle" align="center">Minor allele<br> frequency<br> (Controls)<br> N=721<sup>‡</sup></th><th rowspan="1" colspan="1" valign="middle" align="center">Minor allele<br> frequency<br> (Cases)<br> N=183<sup>‡</sup></th><th rowspan="1" colspan="1" valign="middle" align="center">Odds ratio (95%<br> confidence interval)</th><th rowspan="1" colspan="1" valign="middle" align="center">p-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<em>Intergenic</em>
</td><td rowspan="1" colspan="1" valign="middle" align="center">rs10049478 (G/A)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies A allele</td><td rowspan="1" colspan="1" valign="middle" align="center">5.32E-06</td><td rowspan="1" colspan="1" valign="middle" align="center">0.230</td><td rowspan="1" colspan="1" valign="middle" align="center">0.160</td><td rowspan="1" colspan="1" valign="middle" align="center">0.58 ( 0.43 to 0.80)</td><td rowspan="1" colspan="1" valign="middle" align="center">7.48E-04</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<em>Intergenic</em>
</td><td rowspan="1" colspan="1" valign="middle" align="center">rs1519414 (A/C)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies C allele</td><td rowspan="1" colspan="1" valign="middle" align="center">8.48E-06</td><td rowspan="1" colspan="1" valign="middle" align="center">0.300</td><td rowspan="1" colspan="1" valign="middle" align="center">0.230</td><td rowspan="1" colspan="1" valign="middle" align="center">0.64 ( 0.47 to 0.85)</td><td rowspan="1" colspan="1" valign="middle" align="center">0.002</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<em>Intergenic</em>
</td><td rowspan="1" colspan="1" valign="middle" align="center">rs6703753 (C/T)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies T allele</td><td rowspan="1" colspan="1" valign="middle" align="center">9.23E-06</td><td rowspan="1" colspan="1" valign="middle" align="center">0.260</td><td rowspan="1" colspan="1" valign="middle" align="center">0.190</td><td rowspan="1" colspan="1" valign="middle" align="center">0.70 ( 0.51 to 0.95)</td><td rowspan="1" colspan="1" valign="middle" align="center">0.02</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<em>Intergenic</em>
</td><td rowspan="1" colspan="1" valign="middle" align="center">rs7556683 (T/C)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies C allele</td><td rowspan="1" colspan="1" valign="middle" align="center">3.50E-06</td><td rowspan="1" colspan="1" valign="middle" align="center">0.380</td><td rowspan="1" colspan="1" valign="middle" align="center">0.280</td><td rowspan="1" colspan="1" valign="middle" align="center">0.60 ( 0.45 to 0.78)</td><td rowspan="1" colspan="1" valign="middle" align="center">1.70E-04</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<em>NTN1</em>
</td><td rowspan="1" colspan="1" valign="middle" align="center">rs1880646 (A/G)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies G allele</td><td rowspan="1" colspan="1" valign="middle" align="center">6.83E-06</td><td rowspan="1" colspan="1" valign="middle" align="center">0.300</td><td rowspan="1" colspan="1" valign="middle" align="center">0.210</td><td rowspan="1" colspan="1" valign="middle" align="center">0.62 ( 0.46 to 0.82)</td><td rowspan="1" colspan="1" valign="middle" align="center">8.06E-4</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="center">
<em>RYR2</em>
</td><td rowspan="1" colspan="1" valign="middle" align="center">rs2819742 (G/A)</td><td rowspan="1" colspan="1" valign="middle" align="center"># copies A allele</td><td rowspan="1" colspan="1" valign="middle" align="center">1.30E-06</td><td rowspan="1" colspan="1" valign="middle" align="center">0.380</td><td rowspan="1" colspan="1" valign="middle" align="center">0.270</td><td rowspan="1" colspan="1" valign="middle" align="center">0.48 ( 0.36 to 0.63)</td><td rowspan="1" colspan="1" valign="middle" align="center">1.74E-07</td></tr></tbody></table></div><div id="largeobj_idm140254458922880" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3076530/table/T3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="TFN9"><sup>*</sup>Genome-wide association</div><div id="TFN10"><sup>†</sup>Single nucleotide polymorphism</div><div id="TFN11"><sup>‡</sup>Number of subjects successfully re-genotyped on the TaqMan/pyrosequencing platform.</div></div></div></div><div id="S19" class="sec sec-last"><h3 id="S19title">Exploratory Analyses</h3><p id="P25" class="p p-first"><a href="/pmc/articles/PMC3076530/table/T4/" target="table" class="fig-table-link figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a> displays the results of the significant candidate gene and GWA variants in strata defined by gemfibrozil use. The association of the <em>RYR2</em> variant with cerivastatin-associated rhabdomyolysis was similar in strata defined by gemfibrozil use and there was no evidence of interaction with gemfibrozil use (p=0.439). Among the gemfibrozil users, there was little evidence of association of the <em>SLCO1B1</em> rs4149056 variant with rhabdomyolysis (OR: 0.68, 95%CI: 0.24 to 1.98). Among non-users, the association was strong (OR: 2.45, 95% CI: 1.61 to 3.75) and the interaction p-value was significant (p=0.018). A similar pattern was evident for rs4149033. For all other SNPs, results in analyses limited to non-gemfibrozil users were similar to the results of the primary analysis.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T4"><h3>Table 4</h3><!--caption a7--><div class="caption"><p id="__p8">Analysis of top findings stratified by gemfibrozil use. Models adjusted for age at statin use, sex, and race.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140254456616496" class="xtable"><table frame="hsides" rules="none" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1" valign="middle" align="left"></th><th colspan="4" rowspan="1" valign="middle" align="center">Concomitant gemfibrozil use</th><th colspan="4" rowspan="1" valign="middle" align="center">No gemfibrozil use</th></tr><tr><th colspan="9" rowspan="1" valign="middle" align="left"><hr></th></tr><tr><th rowspan="1" colspan="1" valign="middle" align="left"></th><th rowspan="1" colspan="1" valign="middle" align="center">Minor allele<br> frequency<br> Controls (n=5)</th><th rowspan="1" colspan="1" valign="middle" align="center">Minor allele<br> frequency<br> Cases (n=118)</th><th rowspan="1" colspan="1" valign="middle" align="center">Odds ratio (95%<br> confidence<br> interval)</th><th rowspan="1" colspan="1" valign="middle" align="center">p-<br>value</th><th rowspan="1" colspan="1" valign="middle" align="center">Minor allele<br> frequency<br> Controls<br> (N=716)</th><th rowspan="1" colspan="1" valign="middle" align="center">Minor allele<br> frequency<br> Cases<br> (N=65)</th><th rowspan="1" colspan="1" valign="middle" align="center">Odds ratio (95%<br> confidence<br> interval)</th><th rowspan="1" colspan="1" valign="middle" align="center">p-value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<em>RYR2</em>
</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">rs2819742</td><td rowspan="1" colspan="1" valign="middle" align="center">0.50</td><td rowspan="1" colspan="1" valign="middle" align="center">0.27</td><td rowspan="1" colspan="1" valign="middle" align="center">0.47 (0.12, 1.88)</td><td rowspan="1" colspan="1" valign="middle" align="center">0.29</td><td rowspan="1" colspan="1" valign="middle" align="center">0.378</td><td rowspan="1" colspan="1" valign="middle" align="center">0.269</td><td rowspan="1" colspan="1" valign="middle" align="center">0.52 (0.34, 0.80)</td><td rowspan="1" colspan="1" valign="middle" align="center">0.003</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td colspan="3" rowspan="1" valign="middle" align="center">Interaction p-value = 0.44</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<em>SLCO1B1</em>
</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">rs4149056</td><td rowspan="1" colspan="1" valign="middle" align="center">0.30</td><td rowspan="1" colspan="1" valign="middle" align="center">0.22</td><td rowspan="1" colspan="1" valign="middle" align="center">0.68 (0.24 to 1.98)</td><td rowspan="1" colspan="1" valign="middle" align="center">0.49</td><td rowspan="1" colspan="1" valign="middle" align="center">0.136</td><td rowspan="1" colspan="1" valign="middle" align="center">0.277</td><td rowspan="1" colspan="1" valign="middle" align="center">2.45 (1.61 to 3.75)</td><td rowspan="1" colspan="1" valign="middle" align="center">3.11E-05</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td colspan="3" rowspan="1" valign="middle" align="center">Interaction p-value = 0.02</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">
<em>SLCO1B1</em>
</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left">rs4149033</td><td rowspan="1" colspan="1" valign="middle" align="center">0.40</td><td rowspan="1" colspan="1" valign="middle" align="center">0.22</td><td rowspan="1" colspan="1" valign="middle" align="center">0.41 (0.07 to 2.25)</td><td rowspan="1" colspan="1" valign="middle" align="center">0.30</td><td rowspan="1" colspan="1" valign="middle" align="center">0.213</td><td rowspan="1" colspan="1" valign="middle" align="center">0.354</td><td rowspan="1" colspan="1" valign="middle" align="center">2.17 (1.47 to 3.21)</td><td rowspan="1" colspan="1" valign="middle" align="center">1.08E-04</td></tr><tr><td rowspan="1" colspan="1" valign="middle" align="left"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td colspan="3" rowspan="1" valign="middle" align="center">Interaction p-value = 0.03</td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td><td rowspan="1" colspan="1" valign="middle" align="center"></td></tr></tbody></table></div><div id="largeobj_idm140254456616496" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC3076530/table/T4/?report=objectonly">Open in a separate window</a></div></div><p id="P26">To evaluate if findings change when we control for gemfibrozil use, we re-analyzed our top two findings adjusted for gemfibrozil use. The point estimates remained similar, though precision was reduced due to the small number of controls using gemfibrozil (n=5). Adjusting for gemfibrozil, the point estimate for the significant <em>RYR2</em> variant was 0.50 (95% CI: 0.33 to 0.75) and the point estimate for <em>SLCO1B1</em> rs4149056 was 2.23 (95% CI 1.46 to 3.43).</p><p id="P27">To evaluate the net effect of the <em>RYR2</em> variant rs2819742 and the <em>SLCO1B1</em> variant rs4149056, we included both in the same regression model. The odds ratio for <em>SLCO1B1</em> rs4149056 adjusting for <em>RYR2</em> rs2819742 was 1.86 (95% CI 1.37 to 2.53) and the odds ratio for <em>RYR2</em> rs2819742 adjusting for <em>SLCO1B1</em> rs4149056 was 0.48 (95% CI 0.37 to 0.64). These results suggest that the <em>RYR2</em> and <em>SLCO1B1</em> associations are independent.</p><p id="P28" class="p p-last">Selecting users of statins other than cerivastatin as controls will introduce bias if the decision to prescribe one statin versus another is related to the subjects' genotypes. We evaluated this assumption and found no significant association between the type of statin used and genotype among controls for our two key SNP findings (See <a href="#SD1" rid="SD1" class=" supplementary-material">Table 10, Supplemental Digital Content 1</a>, Distribution of genotype by type of statin among controls).</p></div></div><div id="S20" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S20title">Discussion</h2><p id="P29" class="p p-first">We used candidate-gene re-sequencing and other methods to search comprehensively for known, novel, and rare genetic variants that might underlie cerivastatin-associated rhabdomyolysis. We identified two variants with significant associations: rs2819742 in the <em>RYR2</em> gene and rs4149056 in the <em>SLCO1B1</em> gene. Functional studies corroborated the <em>SLCO1B1</em> finding. For the other candidate genes, <em>CYP2C8</em> and the <em>UGTs,</em> there was little evidence for an association with rhabdomyolysis. The modest associations observed in this study suggest that the manner in which genetic factors affect rhabdomyolysis may be complex, involving multiple genes, interactions, or rare variants outside the candidate pharmacokinetic genes.</p><p id="P30">Though our findings support the hypothesis that underlying genetic factors contribute to extreme adverse drug reactions, we had anticipated finding a number of rare or disabling variants that affected drug-metabolizing enzymes and drug transporters. The <em>CYP2C8</em> gene is predominantly responsible for the first pass oxidative metabolism of cerivastatin [<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102824">8</a>] and contains variant alleles (<em>CYP2C8*2</em>, <em>*3</em>, and <em>*4)</em> which alter the function of the enzyme for some substrates [<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102797">19</a>, <a href="#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102818">20</a>, <a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102825">21</a>-<a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102826">24</a>]. The <em>UGT1A1</em> and <em>1A3</em> glucuronidation is an alternate to the CYP-oxidation pathway for cerivastatin metabolism. Gemfibrozil, which inhibits the cerivastatin oxidation and glucuronidation pathways, was strongly associated with cerivastatin-associated rhabdomyolysis; yet in this study, neither known nor novel genetic variation in <em>UGT1A1</em> or <em>1A3</em> was associated with the risk of rhabdomyolysis and the <em>CYP2C8*2</em>, <em>*3</em>, and <em>*4</em> alleles were less common in cases than controls, though not significantly so. For cerivastatin, these excellent candidate genes did not explain the high incidence of rhabdomyolysis.</p><p id="P31">OATP1B1, the product of <em>SLCO1B1,</em> is a transporter that mediates the hepatic uptake of cerivastatin as well as several other statins [<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102790">10</a>, <a href="#R25" rid="R25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102827">25</a>]. The nonsynonymous coding variant rs4149056 variant slows the uptake of other statins <em>in vitro</em> [<a href="#R26" rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102808">26</a>, <a href="#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102839">27</a>]. In the STRENGTH study, rs4149056 was associated with mild statin induced side effects (including muscle symptoms) among users of simvastatin, atorvastatin and pravastatin [<a href="#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_272200857">28</a>]. A GWA study of myopathy among high-dose simvastatin users [<a href="#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102817">29</a>] found an additional copy of the minor allele of rs4149056 was associated with a 4.5 fold increase in the risk of myopathy (95% CI 2.6 to 7.7). Our study results extend the <em>SLCO1B1</em> rs4149046 findings to cerivastatin-associated rhabdomyolysis, and our functional studies provide additional support for a causal association.</p><p id="P32">Our study results suggest there may be an interaction between <em>SLCO1B1</em> rs4149056 and gemfibrozil use (p=0.02). Analyses limited to subjects using gemfibrozil were null with wide confidence intervals while analyses excluding subjects who used gemfibrozil showed a strong association between rs4149056 and the risk of rhabdomyolysis (OR: 2.45; 95% CI 1.61 to 3.75). While it's difficult to draw strong conclusions about the association between rs4149056 and rhabdomyolysis among gemfibrozil users because there were so few controls using gemfibrozil (n=5), we suspect the exceedingly large effect of gemfibrozil obscured the much smaller genetic association. In our study, gemfibrozil use was associated with a 278 fold increased risk of rhabdomyolysis (95% CI: 106-733). Another study suggested that combined cerivastatin-gemfibrozil use relative to statin monotherapy was associated with a 1411 fold increased risk of rhabdomyolysis [<a href="#R7" rid="R7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102804">7</a>]. The role of <em>SLCO1B1</em> variants was minor relative to the risk associated with the drug-drug interaction.</p><p id="P33">The <em>RYR2</em> gene encodes the ryanodine receptor type 2. The ryanodine receptors are intracellular calcium release channels that are expressed in diverse tissues [<a href="#R30" rid="R30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102796">30</a>]. Three genes encode the different isoforms. <em>RYR1</em> is expressed predominantly in skeletal muscles where it contributes to Ca<sup>2+</sup> signaling and muscle contraction. Variants in <em>RYR1</em> are associated with malignant hyperthermia and central core disease [<a href="#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102793">31</a>]. <em>RYR3</em> but not <em>RYR1</em> expression was found to be upregulated in the skeletal muscle of patients with statin-associated structural muscle injury. The expression of <em>RYR2</em> was not investigated [<a href="#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102814">32</a>]. <em>RYR2</em> is expressed in cardiac muscle and mutations in <em>RYR2</em> are associated with arrhythmogenic right ventricular cardiomyopathy type 2 and stress induced polymorphic ventricular tachycardia [<a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102819">33</a>-<a href="#R35" rid="R35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102833">35</a>]. <em>RYR2</em> is also expressed in the brain [<a href="#R36" rid="R36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102798">36</a>, <a href="#R37" rid="R37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102803">37</a>] and neonatal skeletal muscle [<a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102832">33</a>]. A study in rabbits showed that <em>RYR2</em> expression is upregulated and <em>RYR1</em> expression is downregulated in conditioned muscle [<a href="#R33" rid="R33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102815">33</a>]. In mouse cardiomyocytes, <em>RYR2</em> splice variants can modulate apoptosis, with certain variants reducing Ca<sup>2+</sup> release and preventing apoptosis [<a href="#R38" rid="R38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102805">38</a>]. An apoptotic effect of cerivastatin on skeletal muscle through Ca<sup>2+</sup> release [<a href="#R39" rid="R39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102791">39</a>, <a href="#R40" rid="R40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102829">40</a>] in the presence of genetic variants that either alter <em>RYR2</em> expression or disrupt splice variants suggests potential mechanisms by which <em>RYR2</em> variation might contribute to cerivastatin-associated rhabdomyolysis.</p><p id="P34">Our study had several strengths. We successfully recruited subjects with a rare adverse event. The two control groups had complementary strengths: The CHS controls, like the cases, were geographically diverse; the HVH controls had an age distribution similar to that of the cases. We used multiple approaches--resequencing, tag-SNPs, and functional SNPs--to search for genetic variants of importance in the candidate genes. The resequencing effort had greater than 90% power to detect variants with a minor allele frequency of 1% in the rhabdomyolysis cases and 80% power to detect variants with a minor allele frequency of 0.65% [<a href="#R41" rid="R41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102828">41</a>]. Additionally, we used genome wide scans to identify genetic risk factors outside of the candidate genes.</p><p id="P35">The number of rhabdomyolysis cases, though large for a GWA study of an adverse event [<a href="#R42" rid="R42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102812">42</a>], is nonetheless small and provided limited power to detect associations. To our knowledge, no comparable group of rhabdomyolysis cases was available for replication. Our pre-specified replication plan for the candidate genes was in vitro functional studies (<a href="/pmc/articles/PMC3076530/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>) [<a href="#R43" rid="R43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102831">43</a>]. In one case,a novel <em>CYP2C8</em> variant discovered in the re-sequencing effort introduced a frame shift (which changed the sequence of the last 22 amino acids of the CYP2C8 C-terminus and introduced an additional three amino acids), and this variant likely produced a non-functional protein [<a href="#R43" rid="R43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102837">43</a>]. Recombinant proteins containing two other non-synonymous variants discovered in the <em>CYP2C8</em> re-sequencing had <em>in- vitro</em> kinetic values that were similar to wild type protein. Indeed, recombinant CYP2C8*3 and *4 proteins actually increased the clearance of cerivastatin relative to wild type as has been observed for some other substrates [<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102822">21</a>-<a href="#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102806">24</a>]. The findings of these functional studies may account for the observation that these variants occurred less frequently in cases than controls (ORs, 0.64 to 0.73, <a href="/pmc/articles/PMC3076530/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>).</p><p id="P36">There were other limitations. Most of our controls did not use cerivastatin. The small number of cerivastatin users precluded a detailed examination of an interaction between cerivastatin dose and genotype on rhabdomyolysis risk. The cases selected for this study were not a random sample of rhabdomyolysis patients, but a select population of severe cases who went to litigation. Within this select population, the proportion participating was low. Insofar as the cases included in the study differ genetically or phenotypically from cases that were not, results may generalize poorly. We observed one finding from the GWA study at a p-value threshold at which one false positive is expected. Additional studies will be necessary to corroborate the <em>RYR2</em> finding. The GWA study provided information about common, but not about rare variants, outside the candidate genes. If statin-induced rhabdomyolysis resembles a heterogeneous Mendelian disorder that has several forms caused by genetic variants at many loci in multiple genes - similar to malignant hyperthermia associated with inhalation anesthetics [<a href="#R44" rid="R44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102811">44</a>] or clinical phenylketonuria and dietary phenylalanine [<a href="#R45" rid="R45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102795">45</a>] - we would not have detected it. The focus of this paper was on genetic risk factors for rhabdomyolysis but other environmental exposures, including concomitant medication use, represent additional risk factors of interest.</p><p id="P37" class="p p-last">For the <em>SLCO1B1</em> rs4149056 variant, our results extend the findings for high-dose simvastatin-induced myopathy to cerivastatin-associated rhabdomyolysis. Despite a small sample size for the GWA study, our findings also suggest that disruptions in calcium signaling may be associated with the risk of cerivastatin-associated rhabdomyolysis. <em>RYR2</em> is an interesting candidate for future investigations of statin-related muscle symptoms.</p></div><div id="SM" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="SMtitle">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>Supplementary Material</h4><div class="sup-box half_rhythm" id="N0x5443960N0x6181fe0"><a href="/pmc/articles/PMC3076530/bin/NIHMS265998-supplement-Supplementary_Material.doc" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(595K, doc)</sup></div></div></div><div id="S21" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S21title">Acknowledgements</h2><div class="sec"><p id="__p1">For their excellent work, we thank the attorneys and their staff. We also thank the dedicated staff members at the Cardiovascular Health Research Unit. We thank the rhabdomyolysis case participants, the participants at Group Health, and the participants from the Cardiovascular Health Study.</p><p id="__p2"><strong>Funding Sources:</strong> The rhabdomyolysis case recruitment and the genotyping was supported in part by the grants HL078888, and <a id="__tag_800926395" class="tag_hotlink" href="/nuccore/HL085251" ref="/nuccore/HL085251"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"HL085251","term_id":"1051655659","term_text":"HL085251"}}</span>HL085251</a> from the National Heart, Lung, and Blood Institute. The HVH research reported in this article was supported in part by the grants HL074745, HL43201, <a id="__tag_800926396" class="tag_hotlink" href="/nuccore/HL068639" ref="/nuccore/HL068639"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"HL068639","term_id":"1051623032","term_text":"HL068639"}}</span>HL068639</a>, <a id="__tag_800926397" class="tag_hotlink" href="/nuccore/HL068986" ref="/nuccore/HL068986"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"HL068986","term_id":"1051623379","term_text":"HL068986"}}</span>HL068986</a>, and HL73410 from the National Heart, Lung and Blood Institute. The CHS research reported in this work was supported in part by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC45133 and grant numbers U01 <a id="__tag_800926398" class="tag_hotlink" href="/nuccore/HL080295" ref="/nuccore/HL080295"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"HL080295","term_id":"1051650703","term_text":"HL080295"}}</span>HL080295</a> and R01HL087652 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at <a href="http://www.chs-nhlbi.org/pi.htm" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.chs-nhlbi.org/pi.htm</a>. The CHS DNA handling and genotyping was supported in part by National Center for Research Resources grant M01-RR00425 to the Cedars-Sinai General Clinical Research Center Genotyping core and National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The <em>SLCO1B1</em> functional work was supported in part by NIH grant GM61390 and Amgen Research Fellowship.</p></div></div><div id="idm140254443580976" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140254443580976title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="FN1"></p><p id="P38" class="p p-first-last"><strong>Financial Disclosures:</strong> One author, BMP, worked for plaintiffs' attorneys between 2002 and 2003. A complete statement of disclosure is available in reference <a href="#R6" rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_217102835">6</a>. No other author reported having financial disclosures.</p><p></p><p class="fn sec" id="FN2"></p><p id="P39" class="p p-first-last">This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.</p><p></p></div></div><div id="idm140254461451680" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="idm140254461451680title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="citation">Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated with dexfenfluramine. <span><span class="ref-journal">N Engl J Med. </span>1997;<span class="ref-vol">337</span>:636.</span> [<a href="/pubmed/9280831" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Valvular+heart+disease+associated+with+dexfenfluramine&amp;author=LB+Cannistra&amp;author=SM+Davis&amp;author=AG+Bauman&amp;volume=337&amp;publication_year=1997&amp;pages=636&amp;pmid=9280831&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="citation">Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. <span><span class="ref-journal">Am J Gastroenterol. </span>2003;<span class="ref-vol">98</span>:175–179.</span> [<a href="/pubmed/12526954" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Gastroenterol&amp;title=Incidence+of+idiopathic+acute+liver+failure+and+hospitalized+liver+injury+in+patients+treated+with+troglitazone&amp;author=DJ+Graham&amp;author=CR+Drinkard&amp;author=D+Shatin&amp;volume=98&amp;publication_year=2003&amp;pages=175-179&amp;pmid=12526954&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="citation">Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. <span><span class="ref-journal">Nat Rev Drug Discov. </span>2007;<span class="ref-vol">6</span>:904–916.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2763923/">PMC free article</a>]</span> [<a href="/pubmed/17971785" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Drug+Discov&amp;title=Identifying+genetic+risk+factors+for+serious+adverse+drug+reactions:+current+progress+and+challenges&amp;author=RA+Wilke&amp;author=DW+Lin&amp;author=DM+Roden&amp;author=PB+Watkins&amp;author=D+Flockhart&amp;volume=6&amp;publication_year=2007&amp;pages=904-916&amp;pmid=17971785&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="citation">Meyer UA. Pharmacogenetics and adverse drug reactions. <span><span class="ref-journal">Lancet. </span>2000;<span class="ref-vol">356</span>:1667–1671.</span> [<a href="/pubmed/11089838" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Pharmacogenetics+and+adverse+drug+reactions&amp;author=UA+Meyer&amp;volume=356&amp;publication_year=2000&amp;pages=1667-1671&amp;pmid=11089838&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="citation">Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">346</span>:539–540.</span> [<a href="/pubmed/11844864" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Cerivastatin+and+reports+of+fatal+rhabdomyolysis&amp;author=JA+Staffa&amp;author=J+Chang&amp;author=L+Green&amp;volume=346&amp;publication_year=2002&amp;pages=539-540&amp;pmid=11844864&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="citation">Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. <span><span class="ref-journal">JAMA. </span>2004;<span class="ref-vol">292</span>:2622–2631.</span> [<a href="/pubmed/15572720" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Potential+for+conflict+of+interest+in+the+evaluation+of+suspected+adverse+drug+reactions:+use+of+cerivastatin+and+risk+of+rhabdomyolysis&amp;author=BM+Psaty&amp;author=CD+Furberg&amp;author=WA+Ray&amp;author=NS+Weiss&amp;volume=292&amp;publication_year=2004&amp;pages=2622-2631&amp;pmid=15572720&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="citation">Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. <span><span class="ref-journal">JAMA. </span>2004;<span class="ref-vol">292</span>:2585–2590.</span> [<a href="/pubmed/15572716" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Incidence+of+hospitalized+rhabdomyolysis+in+patients+treated+with+lipid-lowering+drugs&amp;author=DJ+Graham&amp;author=JA+Staffa&amp;author=D+Shatin&amp;author=SE+Andrade&amp;author=SD+Schech&amp;volume=292&amp;publication_year=2004&amp;pages=2585-2590&amp;pmid=15572716&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="citation">Muck W. Clinical pharmacokinetics of cerivastatin. <span><span class="ref-journal">Clin Pharmacokinet. </span>2000;<span class="ref-vol">39</span>:99–116.</span> [<a href="/pubmed/10976657" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacokinet&amp;title=Clinical+pharmacokinetics+of+cerivastatin&amp;author=W+Muck&amp;volume=39&amp;publication_year=2000&amp;pages=99-116&amp;pmid=10976657&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="citation">Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2002;<span class="ref-vol">72</span>:685–691.</span> [<a href="/pubmed/12496749" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacol+Ther&amp;title=Gemfibrozil+greatly+increases+plasma+concentrations+of+cerivastatin&amp;author=JT+Backman&amp;author=C+Kyrklund&amp;author=M+Neuvonen&amp;author=PJ+Neuvonen&amp;volume=72&amp;publication_year=2002&amp;pages=685-691&amp;pmid=12496749&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="citation">Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>2004;<span class="ref-vol">311</span>:228–236.</span> [<a href="/pubmed/15194707" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Pharmacol+Exp+Ther&amp;title=Gemfibrozil+and+its+glucuronide+inhibit+the+organic+anion+transporting+polypeptide+2+(OATP2/OATP1B1:SLC21A6)-mediated+hepatic+uptake+and+CYP2C8-mediated+metabolism+of+cerivastatin:+analysis+of+the+mechanism+of+the+clinically+relevant+drug-drug+interaction+between+cerivastatin+and+gemfibrozil&amp;author=Y+Shitara&amp;author=M+Hirano&amp;author=H+Sato&amp;author=Y+Sugiyama&amp;volume=311&amp;publication_year=2004&amp;pages=228-236&amp;pmid=15194707&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="citation">Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. <span><span class="ref-journal">JAMA. </span>1995;<span class="ref-vol">274</span>:620–625.</span> [<a href="/pubmed/7637142" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=The+risk+of+myocardial+infarction+associated+with+antihypertensive+drug+therapies&amp;author=BM+Psaty&amp;author=SR+Heckbert&amp;author=TD+Koepsell&amp;author=DS+Siscovick&amp;author=TE+Raghunathan&amp;volume=274&amp;publication_year=1995&amp;pages=620-625&amp;pmid=7637142&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="citation">Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K, Lumley T, Bis JC, Wiggins KL, Rosendaal FR, Psaty BM. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. <span><span class="ref-journal">JAMA. </span>2007;<span class="ref-vol">297</span>:489–498.</span> [<a href="/pubmed/17284699" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Association+of+genetic+variations+with+nonfatal+venous+thrombosis+in+postmenopausal+women&amp;author=NL+Smith&amp;author=LA+Hindorff&amp;author=SR+Heckbert&amp;author=RN+Lemaitre&amp;author=KD+Marciante&amp;volume=297&amp;publication_year=2007&amp;pages=489-498&amp;pmid=17284699&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="citation">Heckbert SR, Wiggins KL, Glazer NL, Dublin S, Psaty BM, Smith NL, Longstreth WT, Jr., Lumley T. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. <span><span class="ref-journal">Am J Hypertens. </span>2009;<span class="ref-vol">22</span>:538–544.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2672972/">PMC free article</a>]</span> [<a href="/pubmed/19265792" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hypertens&amp;title=Antihypertensive+treatment+with+ACE+inhibitors+or+beta-blockers+and+risk+of+incident+atrial+fibrillation+in+a+general+hypertensive+population&amp;author=SR+Heckbert&amp;author=KL+Wiggins&amp;author=NL+Glazer&amp;author=S+Dublin&amp;author=BM+Psaty&amp;volume=22&amp;publication_year=2009&amp;pages=538-544&amp;pmid=19265792&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="citation">Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al.  The Cardiovascular Health Study: design and rationale. <span><span class="ref-journal">Ann Epidemiol. </span>1991;<span class="ref-vol">1</span>:263–276.</span> [<a href="/pubmed/1669507" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Epidemiol&amp;title=The+Cardiovascular+Health+Study:+design+and+rationale&amp;author=LP+Fried&amp;author=NO+Borhani&amp;author=P+Enright&amp;author=CD+Furberg&amp;author=JM+Gardin&amp;volume=1&amp;publication_year=1991&amp;pages=263-276&amp;pmid=1669507&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="citation">Andrade SE, Graham DJ, Staffa JA, Schech SD, Shatin D, La Grenade L, Goodman MJ, Platt R, Gurwitz JH, Chan KA. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. <span><span class="ref-journal">J Clin Epidemiol. </span>2005;<span class="ref-vol">58</span>:171–174.</span> [<a href="/pubmed/15680751" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Epidemiol&amp;title=Health+plan+administrative+databases+can+efficiently+identify+serious+myopathy+and+rhabdomyolysis&amp;author=SE+Andrade&amp;author=DJ+Graham&amp;author=JA+Staffa&amp;author=SD+Schech&amp;author=D+Shatin&amp;volume=58&amp;publication_year=2005&amp;pages=171-174&amp;pmid=15680751&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="citation">Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">74</span>:106–120.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1181897/">PMC free article</a>]</span> [<a href="/pubmed/14681826" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=Selecting+a+maximally+informative+set+of+single-nucleotide+polymorphisms+for+association+analyses+using+linkage+disequilibrium&amp;author=CS+Carlson&amp;author=MA+Eberle&amp;author=MJ+Rieder&amp;author=Q+Yi&amp;author=L+Kruglyak&amp;volume=74&amp;publication_year=2004&amp;pages=106-120&amp;pmid=14681826&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="citation">Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">83</span>:311–321.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2842185/">PMC free article</a>]</span> [<a href="/pubmed/18691683" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Hum+Genet&amp;title=Methods+for+detecting+associations+with+rare+variants+for+common+diseases:+application+to+analysis+of+sequence+data&amp;author=B+Li&amp;author=SM+Leal&amp;volume=83&amp;publication_year=2008&amp;pages=311-321&amp;pmid=18691683&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="citation">Peter H.  <span class="ref-journal">Resampling-Based Multiple Testing.</span> Wiley; New York: 1993. Westfall SSY. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Resampling-Based+Multiple+Testing&amp;author=H+Peter&amp;publication_year=1993&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="citation">Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. <span><span class="ref-journal">Biochem Pharmacol. </span>2002;<span class="ref-vol">64</span>:1579–1589.</span> [<a href="/pubmed/12429347" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Pharmacol&amp;title=CYP2C8+polymorphisms+in+Caucasians+and+their+relationship+with+paclitaxel+6alpha-hydroxylase+activity+in+human+liver+microsomes&amp;author=N+Bahadur&amp;author=JB+Leathart&amp;author=E+Mutch&amp;author=D+Steimel-Crespi&amp;author=SA+Dunn&amp;volume=64&amp;publication_year=2002&amp;pages=1579-1589&amp;pmid=12429347&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="citation">Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. <span><span class="ref-journal">Pharmacogenetics. </span>2001;<span class="ref-vol">11</span>:597–607.</span> [<a href="/pubmed/11668219" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenetics&amp;title=Polymorphisms+in+human+CYP2C8+decrease+metabolism+of+the+anticancer+drug+paclitaxel+and+arachidonic+acid&amp;author=D+Dai&amp;author=DC+Zeldin&amp;author=JA+Blaisdell&amp;author=B+Chanas&amp;author=SJ+Coulter&amp;volume=11&amp;publication_year=2001&amp;pages=597-607&amp;pmid=11668219&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="citation">Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2003;<span class="ref-vol">74</span>:380–387.</span> [<a href="/pubmed/14534525" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacol+Ther&amp;title=Polymorphism+in+CYP2C8+is+associated+with+reduced+plasma+concentrations+of+repaglinide&amp;author=M+Niemi&amp;author=JB+Leathart&amp;author=M+Neuvonen&amp;author=JT+Backman&amp;author=AK+Daly&amp;volume=74&amp;publication_year=2003&amp;pages=380-387&amp;pmid=14534525&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="citation">Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2005;<span class="ref-vol">77</span>:468–478.</span> [<a href="/pubmed/15961978" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacol+Ther&amp;title=Polymorphic+organic+anion+transporting+polypeptide+1B1+is+a+major+determinant+of+repaglinide+pharmacokinetics&amp;author=M+Niemi&amp;author=JT+Backman&amp;author=LI+Kajosaari&amp;author=JB+Leathart&amp;author=M+Neuvonen&amp;volume=77&amp;publication_year=2005&amp;pages=468-478&amp;pmid=15961978&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="citation">Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, Jetter A, Stehle S, Tsahuridu M, Meineke I, Brockmoller J, Fuhr U. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2006;<span class="ref-vol">80</span>:657–667.</span> [<a href="/pubmed/17178266" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacol+Ther&amp;title=Pharmacokinetics+and+pharmacodynamics+of+rosiglitazone+in+relation+to+CYP2C8+genotype&amp;author=J+Kirchheiner&amp;author=S+Thomas&amp;author=S+Bauer&amp;author=D+Tomalik-Scharte&amp;author=U+Hering&amp;volume=80&amp;publication_year=2006&amp;pages=657-667&amp;pmid=17178266&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="citation">Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. <span><span class="ref-journal">Drug Metab Dispos. </span>2008;<span class="ref-vol">36</span>:73–80.</span> [<a href="/pubmed/17913794" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Metab+Dispos&amp;title=Trimethoprim+and+the+CYP2C8*3+allele+have+opposite+effects+on+the+pharmacokinetics+of+pioglitazone&amp;author=A+Tornio&amp;author=M+Niemi&amp;author=PJ+Neuvonen&amp;author=JT+Backman&amp;volume=36&amp;publication_year=2008&amp;pages=73-80&amp;pmid=17913794&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="citation">Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. <span><span class="ref-journal">Br J Pharmacol. </span>2009;<span class="ref-vol">158</span>:693–705.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2765590/">PMC free article</a>]</span> [<a href="/pubmed/19785645" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br+J+Pharmacol&amp;title=Impact+of+OATP+transporters+on+pharmacokinetics&amp;author=A+Kalliokoski&amp;author=M+Niemi&amp;volume=158&amp;publication_year=2009&amp;pages=693-705&amp;pmid=19785645&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="citation">Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2006;<span class="ref-vol">16</span>:873–879.</span> [<a href="/pubmed/17108811" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genomics&amp;title=SLCO1B1+polymorphism+markedly+affects+the+pharmacokinetics+of+simvastatin+acid&amp;author=MK+Pasanen&amp;author=M+Neuvonen&amp;author=PJ+Neuvonen&amp;author=M+Niemi&amp;volume=16&amp;publication_year=2006&amp;pages=873-879&amp;pmid=17108811&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="citation">Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2005;<span class="ref-vol">15</span>:513–522.</span> [<a href="/pubmed/15970799" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genomics&amp;title=Functional+characterization+of+SLCO1B1+(OATP-C)+variants,+SLCO1B1*5,+SLCO1B1*15+and+SLCO1B1*15+C1007G,+by+using+transient+expression+systems+of+HeLa+and+HEK293+cells&amp;author=Y+Kameyama&amp;author=K+Yamashita&amp;author=K+Kobayashi&amp;author=M+Hosokawa&amp;author=K+Chiba&amp;volume=15&amp;publication_year=2005&amp;pages=513-522&amp;pmid=15970799&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="citation">Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. <span><span class="ref-journal">J Am Coll Cardiol. </span>2009;<span class="ref-vol">54</span>:1609–1616.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3417133/">PMC free article</a>]</span> [<a href="/pubmed/19833260" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Am+Coll+Cardiol&amp;title=The+SLCO1B1*5+genetic+variant+is+associated+with+statin-induced+side+effects&amp;author=D+Voora&amp;author=SH+Shah&amp;author=I+Spasojevic&amp;author=S+Ali&amp;author=CR+Reed&amp;volume=54&amp;publication_year=2009&amp;pages=1609-1616&amp;pmid=19833260&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="citation">Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">359</span>:789–799.</span> [<a href="/pubmed/18650507" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=SLCO1B1+variants+and+statin-induced+myopathy--a+genomewide+study&amp;author=E+Link&amp;author=S+Parish&amp;author=J+Armitage&amp;author=L+Bowman&amp;author=S+Heath&amp;volume=359&amp;publication_year=2008&amp;pages=789-799&amp;pmid=18650507&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="citation">Brini M. Ryanodine receptor defects in muscle genetic diseases. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2004;<span class="ref-vol">322</span>:1245–1255.</span> [<a href="/pubmed/15336972" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=Ryanodine+receptor+defects+in+muscle+genetic+diseases&amp;author=M+Brini&amp;volume=322&amp;publication_year=2004&amp;pages=1245-1255&amp;pmid=15336972&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="citation">Loke J, MacLennan DH. Malignant hyperthermia and central core disease: disorders of Ca2+ release channels. <span><span class="ref-journal">Am J Med. </span>1998;<span class="ref-vol">104</span>:470–486.</span> [<a href="/pubmed/9626031" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Med&amp;title=Malignant+hyperthermia+and+central+core+disease:+disorders+of+Ca2++release+channels&amp;author=J+Loke&amp;author=DH+MacLennan&amp;volume=104&amp;publication_year=1998&amp;pages=470-486&amp;pmid=9626031&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="citation">Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, Hoppeler H, Breil F, Draeger A. Association between statin-associated myopathy and skeletal muscle damage. <span><span class="ref-journal">CMAJ. </span>2009;<span class="ref-vol">181</span>:E11–18.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2704421/">PMC free article</a>]</span> [<a href="/pubmed/19581603" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=CMAJ&amp;title=Association+between+statin-associated+myopathy+and+skeletal+muscle+damage&amp;author=MG+Mohaupt&amp;author=RH+Karas&amp;author=EB+Babiychuk&amp;author=V+Sanchez-Freire&amp;author=K+Monastyrskaya&amp;volume=181&amp;publication_year=2009&amp;pages=E11-18&amp;pmid=19581603&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R33">33. <span class="citation">Froemming GR, Murray BE, Harmon S, Pette D, Ohlendieck K. Comparative analysis of the isoform expression pattern of Ca(2+)-regulatory membrane proteins in fast-twitch, slow-twitch, cardiac, neonatal and chronic low-frequency stimulated muscle fibers. <span><span class="ref-journal">Biochim Biophys Acta. </span>2000;<span class="ref-vol">1466</span>:151–168.</span> [<a href="/pubmed/10825439" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochim+Biophys+Acta&amp;title=Comparative+analysis+of+the+isoform+expression+pattern+of+Ca(2+)-regulatory+membrane+proteins+in+fast-twitch,+slow-twitch,+cardiac,+neonatal+and+chronic+low-frequency+stimulated+muscle+fibers&amp;author=GR+Froemming&amp;author=BE+Murray&amp;author=S+Harmon&amp;author=D+Pette&amp;author=K+Ohlendieck&amp;volume=1466&amp;publication_year=2000&amp;pages=151-168&amp;pmid=10825439&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R34">34. <span class="citation">Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmbhatt B, Brown K, Bauce B, Muriago M, Basso C, Thiene G, Danieli GA, Rampazzo A. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2) <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:189–194.</span> [<a href="/pubmed/11159936" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Mol+Genet&amp;title=Identification+of+mutations+in+the+cardiac+ryanodine+receptor+gene+in+families+affected+with+arrhythmogenic+right+ventricular+cardiomyopathy+type+2+(ARVD2)&amp;author=N+Tiso&amp;author=DA+Stephan&amp;author=A+Nava&amp;author=A+Bagattin&amp;author=JM+Devaney&amp;volume=10&amp;publication_year=2001&amp;pages=189-194&amp;pmid=11159936&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R35">35. <span class="citation">Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, Marino M, Tiso N, Viitasalo M, Toivonen L, Stephan DA, Kontula K. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. <span><span class="ref-journal">Circulation. </span>2001;<span class="ref-vol">103</span>:485–490.</span> [<a href="/pubmed/11157710" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Mutations+of+the+cardiac+ryanodine+receptor+(RyR2)+gene+in+familial+polymorphic+ventricular+tachycardia&amp;author=PJ+Laitinen&amp;author=KM+Brown&amp;author=K+Piippo&amp;author=H+Swan&amp;author=JM+Devaney&amp;volume=103&amp;publication_year=2001&amp;pages=485-490&amp;pmid=11157710&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R36">36. <span class="citation">Otsu K, Willard HF, Khanna VK, Zorzato F, Green NM, MacLennan DH. Molecular cloning of cDNA encoding the Ca2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. <span><span class="ref-journal">J Biol Chem. </span>1990;<span class="ref-vol">265</span>:13472–13483.</span> [<a href="/pubmed/2380170" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Molecular+cloning+of+cDNA+encoding+the+Ca2++release+channel+(ryanodine+receptor)+of+rabbit+cardiac+muscle+sarcoplasmic+reticulum&amp;author=K+Otsu&amp;author=HF+Willard&amp;author=VK+Khanna&amp;author=F+Zorzato&amp;author=NM+Green&amp;volume=265&amp;publication_year=1990&amp;pages=13472-13483&amp;pmid=2380170&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R37">37. <span class="citation">Nakai J, Imagawa T, Hakamat Y, Shigekawa M, Takeshima H, Numa S. Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel. <span><span class="ref-journal">FEBS Lett. </span>1990;<span class="ref-vol">271</span>:169–177.</span> [<a href="/pubmed/2226801" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FEBS+Lett&amp;title=Primary+structure+and+functional+expression+from+cDNA+of+the+cardiac+ryanodine+receptor/calcium+release+channel&amp;author=J+Nakai&amp;author=T+Imagawa&amp;author=Y+Hakamat&amp;author=M+Shigekawa&amp;author=H+Takeshima&amp;volume=271&amp;publication_year=1990&amp;pages=169-177&amp;pmid=2226801&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R38">38. <span class="citation">George CH, Rogers SA, Bertrand BM, Tunwell RE, Thomas NL, Steele DS, Cox EV, Pepper C, Hazeel CJ, Claycomb WC, Lai FA. Alternative splicing of ryanodine receptors modulates cardiomyocyte Ca2+ signaling and susceptibility to apoptosis. <span><span class="ref-journal">Circ Res. </span>2007;<span class="ref-vol">100</span>:874–883.</span> [<a href="/pubmed/17322175" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Circ+Res&amp;title=Alternative+splicing+of+ryanodine+receptors+modulates+cardiomyocyte+Ca2++signaling+and+susceptibility+to+apoptosis&amp;author=CH+George&amp;author=SA+Rogers&amp;author=BM+Bertrand&amp;author=RE+Tunwell&amp;author=NL+Thomas&amp;volume=100&amp;publication_year=2007&amp;pages=874-883&amp;pmid=17322175&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R39">39. <span class="citation">Inoue R, Tanabe M, Kono K, Maruyama K, Ikemoto T, Endo M. Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers. <span><span class="ref-journal">J Pharmacol Sci. </span>2003;<span class="ref-vol">93</span>:279–288.</span> [<a href="/pubmed/14646245" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Pharmacol+Sci&amp;title=Ca2+-releasing+effect+of+cerivastatin+on+the+sarcoplasmic+reticulum+of+mouse+and+rat+skeletal+muscle+fibers&amp;author=R+Inoue&amp;author=M+Tanabe&amp;author=K+Kono&amp;author=K+Maruyama&amp;author=T+Ikemoto&amp;volume=93&amp;publication_year=2003&amp;pages=279-288&amp;pmid=14646245&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R40">40. <span class="citation">Kobayashi M, Kagawa T, Narumi K, Itagaki S, Hirano T, Iseki K. Bicarbonate supplementation as a preventive way in statins-induced muscle damage. <span><span class="ref-journal">J Pharm Pharm Sci. </span>2008;<span class="ref-vol">11</span>:1–8.</span> [<a href="/pubmed/18445360" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Pharm+Pharm+Sci&amp;title=Bicarbonate+supplementation+as+a+preventive+way+in+statins-induced+muscle+damage&amp;author=M+Kobayashi&amp;author=T+Kagawa&amp;author=K+Narumi&amp;author=S+Itagaki&amp;author=T+Hirano&amp;volume=11&amp;publication_year=2008&amp;pages=1-8&amp;pmid=18445360&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R41">41. <span class="citation">Eberle MA, Kruglyak L. An analysis of strategies for discovery of single-nucleotide polymorphisms. <span><span class="ref-journal">Genet Epidemiol. </span>2000;<span class="ref-vol">19</span>(Suppl 1):S29–35.</span> [<a href="/pubmed/11055367" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genet+Epidemiol&amp;title=An+analysis+of+strategies+for+discovery+of+single-nucleotide+polymorphisms&amp;author=MA+Eberle&amp;author=L+Kruglyak&amp;volume=19&amp;issue=Suppl+1&amp;publication_year=2000&amp;pages=S29-35&amp;pmid=11055367&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R42">42. <span class="citation">Daly AK. Genome-wide association studies in pharmacogenomics. <span><span class="ref-journal">Nat Rev Genet. </span>2010;<span class="ref-vol">11</span>:241–246.</span> [<a href="/pubmed/20300088" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Genet&amp;title=Genome-wide+association+studies+in+pharmacogenomics&amp;author=AK+Daly&amp;volume=11&amp;publication_year=2010&amp;pages=241-246&amp;pmid=20300088&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R43">43. <span class="citation">Kaspera R, Naraharisetti SB, Tamraz B, Sahele T, Cheesman MJ, Kwok PY, Marciante K, Heckbert SR, Psaty BM, Totah RA. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2010;<span class="ref-vol">20</span>:619–629.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2993694/">PMC free article</a>]</span> [<a href="/pubmed/20739906" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacogenet+Genomics&amp;title=Cerivastatin+in+vitro+metabolism+by+CYP2C8+variants+found+in+patients+experiencing+rhabdomyolysis&amp;author=R+Kaspera&amp;author=SB+Naraharisetti&amp;author=B+Tamraz&amp;author=T+Sahele&amp;author=MJ+Cheesman&amp;volume=20&amp;publication_year=2010&amp;pages=619-629&amp;pmid=20739906&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R44">44. <span class="citation">Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. <span><span class="ref-journal">JAMA. </span>2005;<span class="ref-vol">293</span>:2918–2924.</span> [<a href="/pubmed/15956637" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Malignant+hyperthermia:+update+on+susceptibility+testing&amp;author=RS+Litman&amp;author=H+Rosenberg&amp;volume=293&amp;publication_year=2005&amp;pages=2918-2924&amp;pmid=15956637&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R45">45. <span class="citation">Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:831–845.</span> [<a href="/pubmed/17443661" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hum+Mutat&amp;title=The+PAH+gene,+phenylketonuria,+and+a+paradigm+shift&amp;author=CR+Scriver&amp;volume=28&amp;publication_year=2007&amp;pages=831-845&amp;pmid=17443661&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=3076530&amp;issue-id=195824&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar" role="button" aria-expanded="false" aria-haspopup="true">Google Scholar</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="#ui-ncbiinpagenav-heading-3">Associated Data</a></li><li><a href="#idm140254466948512title">Abstract</a></li><li><a href="#S5title">Introduction</a></li><li><a href="#S6title">Methods</a></li><li><a href="#S15title">Results</a></li><li><a href="#S20title">Discussion</a></li><li><a href="#SMtitle">Supplementary Material</a></li><li><a href="#S21title">Acknowledgements</a></li><li><a href="#idm140254443580976title">Footnotes</a></li><li><a href="#idm140254461451680title">References</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC3076530/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC3076530/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC3076530/pdf/nihms-265998.pdf">PDF (352K)</a></li> | <li><a href="#" data-citationid="PMC3076530" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3076530%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3076530%2F&amp;text=Cerivastatin%2C%20Genetic%20Variants%2C%20and%20the%20Risk%20of%20Rhabdomyolysis" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3076530%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="21386754" data-aiid="3076530" data-aid="3076530" data-iid="195824" data-domainid="319" data-domain="nihpa" data-accid="PMC3076530" data-md5="83495f9825a3be1a719ad6b8549f4802"><img src="/portal/portal3rc.fcgi/4018218/img/3631476" alt="Loading..." align="absmiddle"> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-11-20T06:47:02-05:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=portal105&amp;ncbi_phid=CE8CAAFDDD5214A1000000000463029E&amp;ncbi_session=CE8C6010DD4F8B31_0740SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3076530%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 68.1px; left: 377.2px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: block;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: block;">Turn off</a></div></div><div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC3076530/&amp;ncbi_app=pmc" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C6010DD4F8B31_0740SID /projects/PMC/PMCViewer@4.46 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" style="display: none;" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div></body></html>